This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Analyst Reports for Pfizer, Raytheon Technologies & Diageo
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Raytheon Technologies Corporation (RTX), and Diageo plc (DEO).
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) Inks COVID Jab Supply Deal With US Government
by Zacks Equity Research
Novavax (NVAX) inks a deal with the US government to supply 3.2 million doses of COVID shot. But the deal will be effective only if the vaccine gets EUA from the FDA. It also needs CDC recommendation.
Moderna (MRNA) Bivalent COVID Booster Effective Against BA.4/5
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID booster candidate exhibits a higher antibody response against all-tested COVID-19 variants, including the Omicron subvariants BA.4 and BA.5.
Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal
by Zacks Equity Research
Exelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy demonstrates significant improvement in progression-free survival at the primary analysis.
Pfizer (PFE) Stock Moves -0.53%: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $52.89, moving -0.53% from the previous trading session.
PFE, BNTX's COVID Jab Gets FDA's Full Nod for Adolescents
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech's (BNTX) Comirnaty is the first COVID-19 vaccine to receive full approval in the United States for use in adolescents aged 12 years and older.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Pharma Stock Roundup: AZN's Small Cancer Firm Buyout, FDA Updates for PFE, RHHBY
by Kinjel Shah
FDA grants priority review to Roche's (RHHBY) BLA for Lunsumio. AstraZeneca (AZN) announces a small acquisition. Pfizer (PFE) files NDA for Paxlovid.
Biohaven (BHVN) Begins Phase III Study on SMA Candidate
by Zacks Equity Research
Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.
Novavax (NVAX) Stock Rallies 26.8% in a Month: Here's Why
by Zacks Equity Research
FDA's advisory committee supports granting authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. The vaccine also receives authorization for use in adolescents in Europe.
Novavax (NVAX) COVID Jab Receives EU Nod for Adolescents
by Zacks Equity Research
Novavax (NVAX) obtains EU approval for its Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $51.64, marking a -1.28% move from the previous day.
Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?
by Zacks Equity Research
Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.
The Zacks Analyst Blog Highlights Pfizer, BioNTec and Moderna
by Zacks Equity Research
Pfizer, BioNTec and Moderna are part of Zacks Analyst top Blog.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Pfizer (PFE) Seeks FDA Nod for Its Oral Antiviral COVID Pill
by Zacks Equity Research
Pfizer (PFE) submits NDA to the FDA seeking approval for using its oral antiviral COVID pill in vaccinated and unvaccinated patients at a high risk of developing severe COVID-19 complications.
FDA Recommends Adding New Omicron Subvariants to COVID Boosters
by Sundeep Ganoria
In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subvariants.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J
by Zacks Equity Research
Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.
Pfizer (PFE) Inks Deal With US Government for COVID Jab Supply
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech (BNTX) enter into an agreement with the government of the United States to supply 105 million doses of its mRNA-based COVID-19 vaccine.
Pharma Stock Roundup: FDA Panel Backs Updated COVID Jabs, EU Nod for SNY, MRK Drugs
by Kinjel Shah
An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.
The Chef's Warehouse and AZEK have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
The Chef's Warehouse and AZEK are part of as Zacks Bull and Bear of the Day article.